Sitagliptin and cardiovascular outcomes in type 2 diabetes - author's reply

Podobné jednotky

• Correspondence on sitagliptin and cardiovascular outcomes in type 2 diabetes
  Autor: Holman, R, a další
  Vydáno: (2015)
• Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.
  Autor: Holman, R, a další
  Vydáno: (2014)
• Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS.
  Autor: Cornel, J, a další
  Vydáno: (2016)
• Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - authors' reply
  Autor: Nazarzadeh, M, a další
  Vydáno: (2022)
• Assessing the safety of sitagliptin in older participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
  Autor: Bethel, M, a další
  Vydáno: (2017)